Dr. Suraj Timilsina, MD

Dr. Timilsina practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Timilsina's NPI, 1477867869, was assigned on July 28, 2010. Dr. Timilsina graduated from Nepal Medical College in 2006. Dr. Timilsina's California license number on file is A127568.

Dr. Timilsina's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Timilsina's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Timilsina to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Timilsina practices, 3 sites in all. Vendor and product names are available with a free account.

Rheumatology is Dr. Timilsina's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Dr. Timilsina is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Timilsina's licenses on file in 2 states: California and Minnesota.

Dmand AI lists arteritis, arthritis, gout, joint arthropathy, joint pain, lupus, muscle pain, fibromyalgia, and limb pain and purpura and thrombocytopenia among the conditions Dr. Timilsina treats.

CMS data shows 1,323 Medicare services from Dr. Timilsina across 8 procedure codes in 2024, for 446 Medicare patients. Medicare paid $80,331 for them.

CMS counts 446 Medicare patients who saw Dr. Timilsina in 2024. The largest group is 75 to 84, with 176 patients. 75% of them have arthritis, and 68% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Timilsina's median patient age at 58, with 72% women.

In 2024, Dr. Timilsina wrote 2,330 Medicare Part D claims for 342 patients. 78% of them were for generic drugs. CMS names the drug for 2,134 of them, across 31 drugs with 11 or more claims each, at $3,076,633 in total drug cost. In 2023, CMS named 1,866 claims across 25 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Timilsina for performance year 2024, reported as part of a group. Dr. Timilsina accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Timilsina as offering telehealth.

Dmand AI links 16 papers to Dr. Timilsina, published from 2022 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Arthritis, Rheumatoid, Autoimmunity and Gastrointestinal Microbiome. Dr. Timilsina has published most often in Clin Rev Allergy Immunol. Dr. Timilsina's most frequent co-authors are Merrill E. Gershwin, Janet Sue Chou, MD and Christopher L. Bowlus, MD.

CMS Open Payments shows 99 general payments to Dr. Timilsina from 7 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 84% of the total. Abbvie Inc. paid the most, $746.

Dr. Timilsina graduated from Nepal Medical College in 2006. Dr. Timilsina is a member of ACP, ACR and AMA.

Dr. Timilsina is in network with 12 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.